Clinical Trial Update: A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating dovitinib in combination with androgen deprivation therapy for metastatic prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Oscar Goodman, Jr. | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN